Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Inclusion Criteria: * Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation. * HIV-1 infected men and non-pregnant women who are treatment naïve, with positive serology (EIA) confirmed by Western blot. * Age \> 18 and \< 65 years. * CD4 \> 200 cells/mm3 * Viral load (HIV-1 mRNA viral load) \> 5,000 copies/mL. * Ability to swallow multiple large capsules without difficulty. * Acceptable laboratory values that indicate adequate baseline organ function at screening visit. * Laboratory values are considered to be acceptable if the severity of any parameter is = \< Grade 2, based on the DAIDS/ACTG Grading Scale (see Appendix 10.2). * Acceptable medical history, physical examination, and 12-lead ECG at screening * Willingness to abstain from the following starting 2 weeks prior to administration of any study medication and up until the end of the study: o Grapefruit or grapefruit juice, Seville oranges, St. John's Wort, and Milk Thistle. * Willingness to abstain from alcohol 3 days prior to administration of any study medication up to the end of the study. * Willingness to abstain from the following starting 3 days prior to PK sampling: o Garlic supplements and methylxanthine containing foods or drinks (including coffee, tea, cola, energy drinks, chocolate, etc.). * Willingness to abstain from over-the-counter herbal medications for the duration of the study. * Willingness to abstain from any over the counter medication 7 days prior to administration of any study medication (including vitamins, minerals, dietary supplements and antacids) during the study until completion of the post study assessments. Exclusion Criteria: * Female patients of reproductive potential who: * Have positive serum pregnancy test. * Have not been using a barrier method of contraception for at least 3 months prior to participation in the study. * Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial. * Are breast-feeding. * Suspected or documented seroconversion within last 6 months * Participation in another trial with an investigational medicine within 2 months prior to Day 0 of this study. * Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study. * Use of hormone replacement therapy within 1 month prior to Day 0 and anytime during the study. * History of acute illness within 30 days prior to Day 0. * Have evidence of active or acute HBV or HCV. * Alcohol or substance abuse within 1 year prior to screening or during the study. * Patients with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV. * Patients who have taken (within 7 days prior to Day 0) any over-the-counter or prescription medication that, in the opinion of the investigator in consultation with the BI clinical monitor, might interfere with absorption, distribution, or metabolism of the study medications. * Known hypersensitivity to any ingredients of the test drug. * Inability to adhere to the protocol. * Genotypic resistance to tipranavir (defined as a TPV mutation score \> 4).